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IgA nephropathy (IgAN) often shows lesions morphologically
identical with those of focal segmental glomerulosclerosis
(FSGS). In order to determine the possible role of FSGS in IgAN
lesions, we measured glomerular capsular adhesions, often the
first step toward FSGS, in biopsies from 127 patients with IgAN,
100 with lupus nephritis, and 26 with primary FSGS. Capsular
adhesions with no lesions in the underlying tuft, consistent with
podocyte abnormality or loss, were found regularly in FSGS and
IgAN, but infrequently in lupus. Fifteen biopsies of patients with
IgAN were studied immunohistochemically using markers for
podocytes, Bowman’s parietal epithelial cells, proliferating cells,
and macrophages. Cytokeratins CK-8 and C2562 differentiated
normal podocytes (negative) from parietal epithelial cells
(variably positive). There was focal loss of the podocyte markers
synaptopodin, glomerular epithelial protein 1 (GLEPP-1),
nephrin, and vascular endothelial growth factor (VEGF),
particularly at sites of capsular adhesions in otherwise
histologically normal glomeruli. Cells displaying the parietal
epithelial cell markers PAX2 (paired box gene 2) and the
cytokeratins were also positive for the proliferating cell marker,
proliferating cell nuclear antigen. These cells gathered at sites of
adhesion, and in response to active lesions in the tuft, grew
inward along the adhesion onto the tuft, forming a monolayer
positive for parietal markers and the podocyte marker Wilms
tumor protein-1 (WT-1). These cells deposited a layer of
collagen over the sclerosing tuft. Thus, all biopsies of patients
with IgAN had changes basically identical to those classically
described in FSGS. Hence, our study strongly suggests that
podocytopathy of a type similar to that in primary FSGS occurs
frequently in IgAN.
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Two sets of factors have converged in recent times, pointing to
the need for a study of the role of FSGS in IgA nephropathy
(IgAN). First, there are a number of studies describing lesions of
focal segmental glomerulosclerosis (FSGS) in IgAN,1–3 including
post-transplant IgAN.4,5 Haas6 included FSGS as one of the
classes in his classification of IgAN, although this term has been
superseded in the new Oxford classification7,8 by the term
segmental glomerulosclerosis, which subsumes not only lesions
resembling FSGS but other segmental scars, including capsular
adhesions, under this rubric. Furthermore, we found in
preliminary analysis of the series of IgAN patients to be
reported here that roughly half had clearcut lesions either of
FSGS with hyalinosis or collapsing glomerulopathy. We were
also struck, as others have been,7–9 by the frequency of capsular
adhesions in IgAN, a feature found nearly universally in FSGS.
Second, a series of exciting studies has appeared recently
demonstrating deleterious effects of IgA on glomerular
podocytes. Aggregated IgA1 from patients with IgAN inhibits
nephrin expression in podocytes,10,11 mediated through
platelet-derived growth factor,12 and appears to produce
podocyte apoptosis13 as well as reduced adhesive capacity.14
In vitro, not only nephrin but also podocin and synaptopodin
are reduced,13,15 likely mediated through tumor necrosis
factor-a.15 It has also been shown, as indicated in one study
using B-cell lymphoma 2, a proto-oncogene found in
podocytes, that downregulation of podocyte activity is
associated with poor prognosis in IgAN.16
For these reasons we undertook a study of IgAN biopsies to
examine the possible role of FSGS in IgAN. The study is divided
into two parts. The present article deals primarily with
immunohistochemical studies of podocyte and glomerular
parietal epithelial cell (PEC) markers, with attention to capsular
adhesions also. A companion article17 deals with standard light
microscopic studies of IgAN, particularly the parallels with FSGS,
and correlates the findings with clinical and follow-up data.
RESULTS
Glomerular capsular adhesions
To begin to understand the possible role of capsular
adhesions in IgAN, we performed a comparative study of
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our cases of IgAN with biopsies of 100 patients with systemic
lupus erythematosus (SLE), representing an immune com-
plex-mediated process, and of 26 cases of primary FSGS
(Table 1). Capsular adhesions are extremely frequent in all
three conditions as a result of active/proliferative and
sclerosing lesions. However, one aspect in which they differ
markedly is the presence of adhesions without evident
underlying lesions in the tuft (Figure 1a). Such lesions are
infrequent in SLE (8% of cases) and quite common in FSGS
(69.2%), with IgAN intermediate between the two at 41.4%
of cases. The presence of adhesions without underlying
lesions suggests that in some fashion podocytes (or their
absence) may be responsible for the adhesion.
Immunohistochemistry in IgAN
Podocyte markers. All save one of the podocyte markers
used in this study, including synaptopodin, glomerular
epithelial protein 1 (GLEPP-1), nephrin, vascular endothelial
growth factor (VEGF), and Wilms tumor protein-1 (WT-1),
show similar features (the exception is WT-1, described
separately below). It is therefore simplest to discuss them
together, with comments on minor differences. In normal
glomeruli, there is uniform positivity for podocyte markers
along all capillary loops, synaptopodin and nephrin having a
striated appearance along loops cut on the bias, correspond-
ing to the distribution of slit diaphragms and pedicels
(Supplementary Figure S1 online). Staining of rare cells along
Bowman’s capsule is seen, particularly for GLEPP-1 (Figure
1b and e) and synaptopodin (Supplementary Figure S7
online), representing parietal podocytes.18 There may be
isolated diminution or loss of staining in capillary loops,
particularly on the periphery of the tuft in histologically
normal glomeruli (Figure 1b and Supplementary Figure S2
online). Small capillary adhesions to Bowman’s capsule may
occur without loss of staining (Supplementary Figure S4
online), but larger adhesions are invariably attended by
complete loss of podocyte staining (Figure 1c and Supple-
mentary Figure S5 online). In glomeruli with capsular
adhesions and proliferative lesions, podocyte staining may
stop abruptly at points where PECs extend down onto the
surface of the glomerulus (Figure 1c and d). Staining tends to
be preserved more frequently over patent capillary loops than
over areas of endocapillary proliferation, but in advanced
lesions, it is absent from the center of the glomerulus, despite
some still-patent capillaries (Figure 1e). In the majority of
instances, active proliferative or necrotic lesions within the
tuft are overlain by cells staining negatively for all four
podocyte markers (Figure 1c and d and Supplementary
Figures S3, S7 and S8 online). On occasion, one may see
active lesions in which residual synaptopodin-positive or
GLEPP-1-positive cells overlie endocapillary lesions within
the tuft and are in turn overlain by negatively staining cells
(Supplementary Figures S6 online and S10 online). (In other
studies using double-marking techniques, similar overlying
cells in FSGS have been shown to be PECs.19) In advanced
lesions, only vestiges of former podocyte staining remain
and the scarred flocculus is covered by a monolayer of
‘cobblestone’ cells staining negatively for all of the podocyte
markers overlying a band of newly laid down collagen (Figure
1e and Supplementary Figure S9 online). (These cobblestone
cells stain as PECs—see below.) In advanced lesions one may
also see rounded-up cells staining for podocyte markers
(Supplementary Figures S3 online and S9 online) lying free in
Bowman’s space, as well as occasional positive cells along
Bowman’s capsule. Finally, some glomeruli show signs of
simple ischemia, without loss of podocyte markers.
Paired box gene 2 (PAX2). PAX2 marks PECs, with
uniform distribution along the capsule of normal portions
of glomeruli (Supplementary Figure S11 online). There is
proliferation adjacent to capsular adhesions with minor
underlying proliferative lesions (Figure 1f and Supplementary
Figure S11 online). More extensive proliferation along the
adhesions covers the adjacent glomerular tuft in glomeruli
with more extensive tuft lesions (Figure 1g). Usually, a
connection with capsular PECs can be traced or readily
envisioned, but rarely a positive cell will be found in the
center of the flocculus without evident connection to the
capsule (Figure 1g). The rounded-up cells in Bowman’s space
are negative for PAX2 (Figure 1e).
WT-1. WT-1 marks normal podocytes and also stains
capsular epithelium sparsely, presumably parietal podocytes.
In histologically normal glomeruli there may be segments of
the glomerulus from which podocyte staining seems to have
disappeared. WT-1-positive cells proliferate adjacent to
capsular adhesions (Supplementary Figure S13 online).
WT-1 cells are more extensive over more extensive tuft
lesions (Figure 1h), penetrating into the tuft. In advanced
lesions there is a continuous layer of positive cells extending
Table 1 | Comparative study of glomerular capsular adhesions in IgAN, SLE, and primary FSGS
SLE IgAN FSGS
Adhesions 100 biopsies 128 biopsies 26 biopsies
Percent of biopsies No. % Pa No. % Pa No. %
Percent with adhesions 82 82% NS 92 71.9% 0.002 26 100%
Percent with adhesions but without underlying lesions 8 8% 0.0000 53 41.4% 0.006 18 69.2%
Percent with underlying active lesions 49 49% 0.0000 21 16.4% 0.01 10 38.5%
Percent with underlying necrotizing lesions 9 9% 0.003 1 0.8% NS 0 0%
Percent with underlying scarring lesions 59 59% NS 77 60.5% NS 16 64%
Abbreviations: FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; NS, not significant; SLE, systemic lupus erythematosus.
aCalculated using w2 tests.
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Figure 1 | Immunohistochemical studies showing similarities between IgAN and primary FSGS. (a) Capsular adhesions in IgA
nephropathy (IgAN). There are numerous capsular adhesions (arrows) without apparent lesions in the underlying tuft. Mesangial deposits in
this instance are easily recognized by their red staining. (Inset) Frequently, such adhesions appear to exert traction on Bowman’s capsule.
Original magnifications: (Masson’s trichrome (MT))  350, (inset)  650. (b) Focal loss of podocyte staining. Several capillaries (arrows) show
loss of staining, including one with an early adhesion, but without evident lesions in the underlying tuft. Some cells lining Bowman’s
capsule are also positive. Glomerular epithelial protein 1 (GLEPP-1); original magnification  400. (c) Capsular adhesions. Early adhesions
may show only diminution of staining, but larger ones (arrows) show complete loss of synaptopodin staining. Podocyte staining may stop
abruptly at sites of proliferative lesions (top). Synaptopodin; original magnification  350. (d) Loss of podocyte staining over active lesions.
Podocyte staining stops abruptly at the point where proliferative cells coming in from the capsule reach the tuft. A parietal podocyte
(arrow) is positive. GLEPP-1; original magnification  350. (e) Advanced lesion with ‘cobblestone’ epithelium. Monolayer of negatively
staining ‘cobblestone’ epithelium overlies line of new collagenous matrix (arrows) surrounding advanced lesion. Synaptopodin staining has
disappeared from the center of lesion, but a synaptopodin-positive cell lies free in Bowman’s space. Synaptopodin; original magnification
 350. (f) Parietal epithelial cell (PEC) positivity at capsular adhesions. Paired box gene 2 (PAX2)-positive cells are sparsely aligned along
Bowman’s capsule in the lower, normal part of the glomerulus. On top, numerous PAX2-positive cells line the capsule and overlie
proliferative lesion in flocculus. A round cell in Bowman’s space (arrow) is PAX2 negative. PAX2; original magnification  350. (g) PAX2
positivity in advanced lesion. PAX2-positive cells pass from capsule onto glomerulus forming pseudotubules. Most positive cells can be
traced back to the capsule, but rare cells may be found in the interior (arrow) without evident connection to capsule. PAX2; original
magnification  350. (h) Wilms’ tumor protein-1 (WT-1) positivity in active lesion. In the normal (lower) portion of the glomerulus,
podocytes and occasional PECs are positive. On top, extensive WT-1 positivity is seen along capsule and over tuft lesion. WT-1; original
magnification  350. (i) Proliferation of proliferating cell nuclear antigen (PCNA)-positive cells. Numerous positive cells, some definitely PECs
and others presumptively PECs, overlie an area of glomerular necrosis. PCNA; original magnification  300. (j) Advanced lesion. Proliferated
PCNA-positive cells overlying an active lesion (upper left) are positive. Some ‘cobblestone’ cells (right) are positive, and others are not. A
PCNA-positive round cell (arrow) lies free in Bowman’s space. PCNA; original magnification  350. (k) Cytokeratin-positive cells at site of
adhesion. Cells behaving as PECs proliferate at the site of adhesion. C2562; original magnification  350. (l) Advanced lesion. PECs and
cobblestone cells show strong positivity. Arrows indicate layer of collagenous matrix overlying advanced lesion. CK-8; original magnification
 350.
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from the capsule over the damaged tuft (Supplementary
Figure S12 online), largely coextensive with PAX2 staining,
with both marking cells aligned along the bands of new
collagen overlying the damaged tuft (Supplementary Figures
S12 online, S13 online), in the instance of WT-1 on both
sides of the layer. Occasional round cells staining positively
for WT-1 may be seen free in Bowman’s space.
Proliferating cell nuclear antigen (PCNA). In normal
glomeruli, modest numbers of intraluminal cells (some
definitely endothelial), mesangial cells, and PECs are positive.
No definite podocyte staining is seen at any point in the
evolution of lesions. In glomeruli with segmental cellular
lesions, PECs lining the capsule show marked proliferation,
continuous with numerous cells, also presumptively PECs,
overlying the affected area (Figure 1i). In advanced lesions,
PECs and cobblestone cells overlying the tuft are widely but
not invariably positive (Figure 1j). Occasional round cells
lying free in Bowman’s space also stain (Figure 1j).
Cytokeratins (CK-8 and C2562). CK-8 and C2562, which
recognizes nine different cytokeratins including CK-8, were
used in the confirmation of identification of PECs. Normal
podocytes are negative for both. When positive, both CK-8
and C2562 identified PECs, either in their normal capsular
position or behaving as PECs as shown by PAX2 positivity in
adjacent sections. CK-8 staining was more extensive than
C2562, which in normal glomeruli showed only focal
positivity, primarily in cells near the hilar pole. Neither
antiserum stained normal or reactive PECs universally, even
in normal controls, and hence only positive staining was
helpful in identification. With that proviso, we found freq-
uent accumulations of CK-8- and C2562-positive cells
around the affected tuft at adhesion sites (Figure 1k and
Supplementary Figure S14 online). The cobblestone, pseu-
dotubular arrangements around advanced lesions could be
markedly positive (Figure 1l), but other advanced lesions
were only modestly positive, with some cells staining and
others not (Supplementary Figure S15 online).
CD68. CD68-positive cells with morphologic features of
PECs may be recognized in early lesions, with occasional
positive cells free in Bowman’s space (Supplementary Figure
S16 online). Rarely is there positive staining underlying
epithelial cells, but there is no staining of podocytes in their
normal positions. Similarly, in advanced lesions, there is only
isolated staining in the capsular and cobblestone layers
(Supplementary Figure S16 online).
DISCUSSION
Interpretation of immunohistochemical study results
Overall, the pattern is one of progressive loss of the
podocyte markers, synaptopodin, GLEPP-1, nephrin, and
VEGF, beginning very early in isolated capillary loops and at
sites of adhesion, before there are recognizable signs of lesions
in the underlying flocculus. There is near-total loss of
podocyte markers over more advanced lesions, as for example
in ‘cobblestone’ and pseudotubule regions. In contrast, PAX2,
a marker of PECs, shows progressive increase, from early
positivity at sites of adhesion to more diffuse positivity over
active tuft lesions. There is continuity between the positive
cells directly overlying the tuft lesion and capsular cells,
suggesting they are all of PEC origin. The pattern of
proliferating cell nuclear antigen positivity parallels that of
PAX2, although not all cells stain. Cytokeratin CK-8 and
C2562 positivity, although more variable, parallels that of
PAX2 as well. WT-1 shows behavior intermediate between
standard podocyte markers and PEC markers, with definite
loss of podocyte marking at sites of adhesion, but progres-
sively increasing positivity with advancing glomerular lesions,
paralleling that of PAX2. The nature of the WT-1-positive
cells in the areas of cellular proliferation may be questioned.
The fact that WT-1 staining is largely coextensive with PAX2
and that staining for podocyte markers in these areas is
negative, suggests that here WT-1 is marking primarily cells
acting as PECs, but double-staining techniques would be
required to completely rule out a role for altered podocytes.
Immunohistochemical profile of glomerular lesions in FSGS
Early immunohistochemical studies of FSGS documented
loss of podocytic markers such as synaptopodin, podocalyx-
in, and GLEPP-1 over the affected areas of the tuft.20 These
changes were attributed to podocyte dysregulation. Barie´ty
et al.21–23 confirmed these findings, adding to them several
important observations. First, the so-called ‘cobblestone’
epithelium overlying areas of advanced tuft lesions was
negative for podocyte markers. Second, they identified
rounded macrophage-like cells lying free in Bowman’s space,
having podocytic markers identifying their podocytic origin.
These cells also acquired macrophagic epitopes, and could
later be found in the tubular lumens. Third, they demon-
strated in elegant fashion that there was transdifferentiation
of cells, identifying cells expressing simultaneously podocyte
markers and macrophagic markers or cytokeratins.22 They
also felt that this transdifferentiation could be regarded as
a form of podocyte dysregulation. Another early study24
described increase of PAX2 and cytokeratin over cellular
lesions and in cobblestone epithelium, attributing these
findings to re-expression of PAX2 in podocytes.
These observations have stood up with time, but their
interpretation has changed away from the notion of podocyte
dysregulation. The emergence of reliable markers for PECs,
such as PAX219,25 and CK-8,25 has permitted the recognition
that many of the cells covering the glomerular tuft are not
podocytes, but rather PECs. Dijkman et al.,19,25 using PAX2,
CK-8, and podocyte markers, together with painstaking
serial-section reconstruction of glomeruli in FSGS and
collapsing glomerulopathy, demonstrated that the anomalous
cells overlying the tuft are in fact PECs that have grown in
along capsular adhesions to cover the tuft, surrounding areas
of floccular damage and forming the flattened cobblestone
layer seen in late lesions. A crucial aspect of their
reconstructions is that adhesions and PEC ingrowth can
invariably be found if one searches hard enough. This
observation effectively rules out the notion of podocyte
638 Kidney International (2011) 79, 635–642
or ig ina l a r t i c l e GS Hill et al.: Role of FSGS in IgAN
phenotypic changes or dysregulation as an explanation for the
lesions in FSGS. Furthermore, they demonstrated that the layer
of new collagen typically laid down over the sclerosing lesions
in FSGS is identical with the collagen of Bowman’s capsule that
is known to be elaborated by PECs.19 Later experimental
studies using genetically labeled PECs confirmed their role in
crescentic glomerulonephritis and collapsing glomerulopathy,
to the near exclusion of podocytes.26
Thus, the pathogenesis of FSGS now seems clearly related
to loss of podocyte markers on the one hand and aggression
of the tuft by PECs on the other. (These observations may be
further refined in the future, with the recent identification of
renal progenitor cells lying along Bowman’s capsule with the
ability to transform into podocytes or tubular cells depend-
ing on their position,27,28 and may possibly have a role in
repair and regeneration of podocytes.)
Immunohistochemical observations in IgAN
Our observations in IgAN regarded as a podocytopathy are,
with only minor exceptions (see below), completely con-
sistent with current views on FSGS. (In addition, because our
series contained a number of early/mild cases, we have been
able to make some observations regarding IgAN that seem
likely to apply to FSGS as well, although they have not been
commented upon specifically in the literature on FSGS.)
First and foremost, as detailed in the companion article to
this one,17 we have identified examples of all of the major
variants of FSGS as currently classified,29 including hyalinosis
lesions, collapsing glomerulopathy, and tip lesions. Second,
in this study we have identified focal loss of podocyte
markers (synaptopodin, GLEPP-1, nephrin, and VEGF) early
on, along peripheral capillary loops and particularly at the
sites of capsular adhesions, in the absence of overt lesions
within the tuft. Importantly, this loss involves not only the
immediate area of the adhesion, but for at least a short
distance away. Loss of podocyte markers has been commen-
ted upon extensively in FSGS19–23,25,30 and to a lesser extent
in IgAN,30–34 but focal early loss has not been specifically
commented upon in light microscopic studies. However,
focal loss of podocyte markers has been described by electron
microscopy in a study utilizing immunogold-labeled nephrin
in a variety of diseases including FSGS, showing that nephrin
was absent from areas of foot process fusion and present in
areas with preserved foot processes.35 Loss of podocytes at
points of adhesion has been extensively described in
experimental FSGS,36,37 but not specifically in humans,
although various theories of pathogenesis presume its
occurrence.36,38,39 Third, we have observed early proliferation
of cells staining for PAX2, cytokeratins, WT-1, and
proliferating cell nuclear antigen at these points of adhesion,
with extension of these cells along the adhesion onto the
adjacent tuft. These findings parallel those of Dijkman
et al.19,25 who with their serial reconstructions in FSGS were
able to demonstrate that there is always continuity with the
capsular PECs. We have further shown that the epithelial cells
overlying active lesions, the so-called ‘cobblestone’ epithe-
lium, stain negatively for podocyte markers and positively
for PAX2 as PECs, a finding entirely consistent with the
studies of FSGS and collapsing glomerulopathy previously
cited.19–23,25 Finally, we have confirmed the presence
of free round cells in Bowman’s space marking both for
podocyte and macrophagic markers, although on separate
stains. Double-labeling studies would be required to
confirm that these cells simultaneously express both podocyte
and macrophagic markers as has been demonstrated
in FSGS.22,23
One potential difference between our results and previous
studies of FSGS is that we did not observe as widespread
positivity for cytokeratin in cells behaving as PECs as described
in the studies of Dijkman et al.19,25 Our CK-8 and C2562 when
positive did indeed identify cells behaving as PECs and doing
all of the things that Dijkman et al. described, such as
proliferating at sites of adhesions and forming ‘cobblestone’
monolayers over advanced lesions.19,25 However, staining was
not universal, even in normal glomeruli in our controls. It
seems reasonable to posit that these differences reflect the
different antisera used in the two studies.
Another minor difference is that we do not see quantities
of cells with macrophagic epitopes covering the tuft, as
described by Barie´ty et al.40 However, Dijkman et al.19
specifically commented on their absence in their study of
FSGS. The reason for this disparity is not evident, parti-
cularly as both groups studied FSGS recrudescent in
transplanted kidneys.
Glomerular capsular adhesions
Many authors have commented on the prominence of
capsular adhesions in IgAN,7–9,41 so much so that they are
included in the Oxford classification definition of segmental
glomerulosclerosis,7,8 but they have not previously been
investigated systematically. As indicated in Table 1, in all
three conditions studied, IgAN, SLE, and FSGS, adhesions
were extremely common over areas of active glomerular
lesions and scarring, as in other diseases. More importantly,
however, in FSGS and IgAN they were frequently found over
capillary loops without evidence of underlying lesions,
suggesting an abnormality in the podocytes, rather than
any underlying inflammatory or cicatricial lesion.
That these are real adhesions, and not simply an artifact of
the biopsy procedure and processing, is attested to not only
by their frequency compared with SLE biopsies, but also by
the fact that in fortunate sections they can be seen to exert
traction on the capsule (Figure 1a). They also create the
pathway by which PECs penetrate onto the glomerular tuft
and proliferate, parallel to that seen in FSGS.19,25 These
adhesions seem to provide the key to why IgAN so often
behaves in a fashion parallel to FSGS.
Role of loss of podocytes in IgAN
Kriz and coworkers have developed a model of ‘classical’ FSGS,
as summarized in the work of Kriz.36 They demonstrated in a
variety of animal models loss of podocytes with denuding of
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the glomerular basement membrane and adherence to
Bowman’s capsule, which they regarded as the first ‘committed
step’ in FSGS. Podocyte damage has also been shown to lead to
capsular adhesions in experimental Masugi nephritis42,43 and a
model of glomerulosclerosis in which diphtheria toxin leads to
destruction of podocytes in a dose-dependent fashion.43 Our
study has shown podocyte loss in IgAN in an elementary
fashion, first by diminution and disappearance of podocyte
staining, and second by the presence of free cells with
podocyte markers in Bowman’s space as has been previously
reported in FSGS.21,22 More quantitative approaches have been
employed in IgAN, one by counting glomerular podocytes on
biopsy, and the other by measuring cumulative excretion
of podocytes in the urine,44 both demonstrating that loss of
podocytes is accompanied by disease progression. Yet, other
studies have linked podocyte loss in IgAN to prognosis.45
Abnormal IgA1 as a pathogenetic factor in lesions of FSGS
in IgAN
Although our immunohistochemistry results show strong
parallels between IgAN and primary FSGS phenotypically,
there are differences between the two. For example, one study
has shown that in IgAN the extracellular domain of nephrin,
a membrane protein, is virtually abolished whereas the
intracellular domain remains intact, although in FSGS both
domains seem intact.31 This is consistent with the recent
studies showing that aggregated IgA1 from IgAN patients
reduces nephrin expression,10,11 and IgA1 exerts other
deleterious effects on podocytes as well.13–15
This makes it seem likely that abnormal IgA1 is at the root
of the pathogenesis of podocytopathy in IgAN. Should this be
the case, abnormal IgA1 would join a long list of patho-
genetic factors, including heritable mutations of podocyte-
specic proteins, drug toxicity, infections, and adaptive
responses to reduced functioning renal mass, capable of
producing the morphologic picture of FSGS.29,46,47
In conclusion, this study concludes that the podocyte and
PEC alterations seen in IgAN are basically identical with
those seen in primary FSGS, and it relates them to
progression of disease. Podocyte changes begin focally, not
previously appreciated, and with progression of lesions,
podocytes are progressively lost and replaced by PECs, giving
a morphologic basis for earlier morphologic and clinical
studies showing podocyte loss. These changes form a
theoretical basis on which recent in vitro observations on
the role of IgA1 in podocyte damage might be related to the
lesions seen on biopsy.
PATIENTS AND METHODS
Patients
All the adult (418 years) patients diagnosed with IgAN from
January 2002 to January 2008 in the Pathology Department
of Georges Pompidou European Hospital were enrolled in
this study. These biopsies came from four different medical
centers. The diagnosis was based on the presence of predomi-
nant IgA and C3 deposits in the mesangium. Patients
with SLE, Henoch–Scho¨nlein purpura, chronic liver disease,
or human immunodeficiency virus infection were excluded,
as well as patients whose renal biopsy specimen contained
o8 glomeruli, leaving a total of 128 patients. A wide variety
of clinical and laboratory data were gathered, as reported in
the companion article17, but are not relevant to the present
study focusing on immunohistochemical studies.
Table 2 | Definitions of Oxford criteria for IgAN and of the
Columbia classification of FSGS as applied to IgAN
Oxford criteria for IgAN
Term Definition
Mesangial
hypercellularity
4 4 to 5 mesangial cells/mesangial area in450%
of glomeruli
Segmental
glomerulosclerosis
Any amount of the tuft involved in sclerosis, but
not involving the entire tuft or the presence of an
adhesion, in 1 glomeruli
Endocapillary
hypercellularity
Hypercellularity due to increased number of cells
within glomerular capillary lumina causing
narrowing of the lumina, segmental or diffuse in
at least one glomerulus, graded as present/absent
from biopsy.
Tubular atrophy/
interstitial fibrosis
Percentage of cortical area involved by tubular
atrophy or interstitial fibrosis, whichever is greater
T0, 0–25%; T1, 26–50%; and T2, 450%
Columbia classification of FSGS in the context of IgAN
Variant Inclusion criteria
Exclusion
criteria
FSGS, NOS At least 1 glomerulus with segmental
increase in matrix obliterating the capillary
lumina, or segmental glomerular capillary
collapse, associated with hyalinosis lesions
and/or epithelial hypertrophy/hyperplasia.a
Exclude
perihilar,
cellular, tip,
and
collapsing
variants.
Perihilar
variant
At least one glomerulus with perihilar
hyalinosis, with or without sclerosis. Also,
450% of glomeruli with segmental lesions
must have perihilar sclerosis and/or hyalinosis.
Exclude
cellular, tip,
and collapsing
variants.
Cellular
variant
At least one glomerulus with segmental
endocapillary hypercellularity occluding
lumina, with or without foam cells and
karyorrhexis, with hyperplasia of overlying
epithelium.b
Exclude tip
and
collapsing
variants.
Tip variant At least 1 segmental lesion involving the tip
domain (outer 25% of tuft next to origin of
proximal tubule). The tubular pole must be
identified in the defining lesion. The lesion
must have either an adhesion or confluence
of podocytes with parietal or tubular cells
at the tubular lumen or neck. Tip lesion
may be cellular or sclerosing.
Exclude
collapsing
variant and
any
perihilar
sclerosis.
Collapsing
variant
At least 1 glomerulus with segmental or
global collapse and overlying podocyte
hypertrophy and hyperplasia.
None
Abbreviations: FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy;
NOS, not otherwise specified.
aAdded to exclude segmental scars of possible non-FSGS origin.
bAdded to exclude endocapillary proliferation of possible non-FSGS origin.
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Renal histopathology
The renal biopsies were processed for light microscopy and
direct immunofluorescence. Tissue for histology was fixed
in acetic acid/formol/absolute alcohol fixative, paraffin
embedded, and stained by standard techniques. Sections
(6mm) were stained for immunofluorescence study with
fluorescein isothiocyanate-conjugated antibodies specific for
human IgG, IgM, IgA, C1q, C3, k and l light chains,
and fibrin (DAKO, Carpinteria, CA). All biopsy slides were
re-reviewed by two senior pathologists (DN and GH) without
knowledge of clinical outcomes. The biopsies were graded
according to the Oxford classification of IgAN7,8 (Table 2).
Glomerular lesions were also evaluated in terms of possible
lesions of FSGS, using the proposed 2004 classification of
FSGS,29 as adapted to the setting of IgAN (Table 2). The
following types were distinguished: (1) FSGS, NOS (not
otherwise specified); (2) FSGS, perihilar variant, with
hyalinosis lesions at the glomerular hilus; (3) FSGS, cellular
variant; (4) FSGS, tip lesion; and (5) FSGS, collapsing
glomerulopathy. We also performed a comparative study of
capsular adhesions in our IgAN cases, plus 100 biopsies of
patients with severe lupus nephritis, from a previous study, and
26 cases of primary FSGS. For each biopsy, the different types of
lesions in the underlying adherent lobule were noted (none;
proliferative; necrotizing; scarring, with or without hyalinosis).
Capsular adhesions were evaluated as follows: those points where
adherence of the capillary to the capsule was accompanied by
epithelial proliferation were considered definite adhesions, as
were those where evident traction was exerted on the capsule.
Other points of touching of the capillary to the capsule with
evident open Bowman’s space on either side were also considered
positive. Where Bowman’s space was obliterated, often relating to
biopsy technique, this determination could not be made.
Immunohistochemical studies
Patient selection. A total of 15 biopsies were studied using
immunohistochemistry. They were selected so as to display
the entire spectrum of abnormalities on light microscopy,
particularly cellular and collapsing variants, as well as cases
with mild mesangial lesions with adhesions. They did not
differ significantly from the overall group in terms of
proteinuria or serum creatinine at diagnosis.
Immunohistochemistry markers
Podocytes were characterized using an anti-synaptopodin
monoclonal antibody (mAb), clone G1D4 (Biogen and
Biotechnik, Heidelberg, Germany), an anti-GLEPP-1 mAb,
clone 5C11 (Biogenex, San Ramon, CA), an anti-human
nephrin N-20 polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA), an anti-human VEGF-C mAb, clone C1
(Santa Cruz Biotechnology), and an anti-human WT-1
polyclonal antibody, C-19 (Santa Cruz Biotechnology) directed
against the transcription factor WT-1 normally expressed in
mature podocytes. PECs were characterized using an anti-
human PAX2 polyclonal antibody (Zymed, San Francisco, CA),
a transcription factor expressed in normal PECs and fetal
immature podocytes, and lost in mature podocytes. Cytoker-
atins were labeled using CK-8 (Zymed, Carlsbad, CA) and
C2562 mAb cocktail (Sigma Aldrich, Saint Quentin Fallavier,
France) that was directed against nine cytokeratin types,
including CK-8. Macrophagic epitopes were identified
using an anti-CD68 mAb, clone PGM1 (Dakopatts, Glostrup,
Denmark). Immunohistochemistry procedures were performed
as described previously.23 The different markers used are listed
in Table 3.
Statistical methods
Differences between percentages of capsular adhesions
(Table 1) were evaluated using w2 tests. A value of Po0.05
was considered significant.
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SUPPLEMENTARY MATERIAL
Figure S1. Normal glomerulus.
Figure S2. Early loss of podocyte staining.
Figure S3. Early loss of podocyte staining.
Figure S4. Focal capsular adhesion without loss of podocyte staining.
Figure S5. Capsular adhesions with loss of podocyte staining.
Figure S6. Negatively staining cell overlying synaptopodin positive
podocytes.
Figure S7. Glomerulus with varied lesions.
Figure S8. Advanced lesion.
Figure S9. Advanced lesion stained for synaptopodin.
Figure S10. Advanced lesion stained for GLEPP-1.
Figure S11. Parietal epithelial cells (PECs).
Figure S12. WT-1 staining in active lesion.
Figure S13. WT-1 staining in advanced lesion.
Figure S14. Possible tip lesion.
Figure S15. Advanced lesion with variable CK-8 staining.
Figure S16. CD68 in PECs.
Table 3 | Cellular markers used in this study
Podocyte plasma membrane proteins
Podocalyxin
GLEPP-1
Slit-diaphragm-associated protein
Nephrin
Cytoskeleton-associated pedicel protein
Synaptopodin
Protein synthesized by podocyte
VEGF
Parietal epithelial cells
PAX2
Cytoskeleton intermediate filaments
Cytokeratins (CK-8, C2562, a mixture of 9 cytokeratins, including CK-8)a
Transcription factors
WT-1
Macrophage epitopes
CD68
Abbreviations: GLEPP-1, glomerular epithelial protein-1; PAX2, paired box gene 2;
VEGF, vascular endothelial growth factor; WT-1, Wilms tumor protein-1.
aVariable staining of normal parietal epithelial cells (PECs); normal podocytes
negative.
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